WO2018087143A3 - Anti-pd-1 antibodies - Google Patents

Anti-pd-1 antibodies Download PDF

Info

Publication number
WO2018087143A3
WO2018087143A3 PCT/EP2017/078595 EP2017078595W WO2018087143A3 WO 2018087143 A3 WO2018087143 A3 WO 2018087143A3 EP 2017078595 W EP2017078595 W EP 2017078595W WO 2018087143 A3 WO2018087143 A3 WO 2018087143A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
relates
immunoconjugates
bind
therapeutic
Prior art date
Application number
PCT/EP2017/078595
Other languages
French (fr)
Other versions
WO2018087143A2 (en
Inventor
Alex Duncan
Matthew Mccourt
Michael Dyson
John Blackwood
Original Assignee
Actigen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actigen Ltd filed Critical Actigen Ltd
Priority to EA201990978A priority Critical patent/EA201990978A1/en
Publication of WO2018087143A2 publication Critical patent/WO2018087143A2/en
Publication of WO2018087143A3 publication Critical patent/WO2018087143A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to antibodies that bind to PD-1. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic and diagnostic purposes.
PCT/EP2017/078595 2016-11-08 2017-11-08 Anti-pd-1 antibodies WO2018087143A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201990978A EA201990978A1 (en) 2016-11-08 2017-11-08 ANTIBODIES AGAINST PD-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1618833.6 2016-11-08
GB201618833 2016-11-08

Publications (2)

Publication Number Publication Date
WO2018087143A2 WO2018087143A2 (en) 2018-05-17
WO2018087143A3 true WO2018087143A3 (en) 2018-12-13

Family

ID=60388022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/078595 WO2018087143A2 (en) 2016-11-08 2017-11-08 Anti-pd-1 antibodies

Country Status (2)

Country Link
EA (1) EA201990978A1 (en)
WO (1) WO2018087143A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
BR112021013157A8 (en) * 2019-01-03 2022-12-06 Inst Nat Sante Rech Med USES OF AN NRP-1 INHIBITOR, USE OF A COMBINATION, USE OF A MULTIESPECIFIC ANTIBODY, EX VIVO METHOD TO PREDICT, USE OF AN INHIBITOR, MULTIESPECIFIC ANTIBODY, MODIFIED CELL POPULATION, EX VIVO METHOD OF PRODUCTION AND USE OF A POPULATION OF T CELLS
WO2021006199A1 (en) 2019-07-05 2021-01-14 小野薬品工業株式会社 Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016113556A1 (en) * 2015-01-12 2016-07-21 Crescendo Biologics Limited Methods for producing optimised therapeutic molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016113556A1 (en) * 2015-01-12 2016-07-21 Crescendo Biologics Limited Methods for producing optimised therapeutic molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. WANG ET AL: "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 9, 28 May 2014 (2014-05-28), pages 846 - 856, XP055206944, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0040 *
KATHLEEN M. MAHONEY ET AL: "The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma", CLINICAL THERAPEUTICS., vol. 37, no. 4, 1 April 2015 (2015-04-01), US, pages 764 - 782, XP055285031, ISSN: 0149-2918, DOI: 10.1016/j.clinthera.2015.02.018 *
ROY L MAUTE ET AL: "Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,, vol. 112, no. 47, 1 November 2015 (2015-11-01), pages E6506 - E6514, XP002772779, ISSN: 0027-8424, DOI: 10.1073/PNAS.1519623112 *
TERESA C. LONGORIA ET AL: "Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol. 12, no. 10, 16 August 2016 (2016-08-16), GB, pages 1247 - 1253, XP055516478, ISSN: 1742-5255, DOI: 10.1080/17425255.2016.1216976 *

Also Published As

Publication number Publication date
EA201990978A1 (en) 2019-12-30
WO2018087143A2 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
WO2016077397A3 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
MX2022008184A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment.
MX2018016364A (en) Anti-pd-l1 antibodies.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018501177A1 (en) Antibodies targeting fc receptor-like 5 and methods of use
MX2018012757A (en) Agonistic antibodies that bind human cd40 and uses thereof.
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
WO2016014688A3 (en) Anti-pd-1 antibodies
MX2018003936A (en) Anti-pd-1 antibodies and compositions.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2022014914A (en) Glycan-interacting compounds and methods of use.
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2022008523A (en) Glycan-interacting compounds and methods of use.
PH12016501366A1 (en) Novel anti-baff antibodies
WO2018087143A3 (en) Anti-pd-1 antibodies
MX2018015265A (en) Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders.
WO2018094300A8 (en) Anti-gitr antigen-binding proteins and methods of use thereof
PH12019502694A1 (en) Anti-trkb antibodies
MX2018009218A (en) Cgrp antibodies and uses thereof.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17800783

Country of ref document: EP

Kind code of ref document: A2